GobyMeds vs MEDVi

Recorded prices, access and terms.

Decision table

The entries below are recorded provider statements unless a regulatory source is linked. A provider webpage does not independently verify its licenses or quality. GobyMeds source · MEDVi source.

CompareGobyMedsMEDVi
Recorded medication/program subtotalMonthly-plan rate unconfirmed. Advertised headline prices may require prepayment, a specific dose or introductory terms. Full required cost is unconfirmed.Recorded medication and program subtotal — semaglutide: $299/month. Other required fees, labs, dose changes and renewal terms: unconfirmed. This is not a verified all-in treatment cost.
Full required monthly costUnconfirmed: consultation, labs, membership, dose changes and shipping must be checkedUnconfirmed: consultation, labs, membership, dose changes and shipping must be checked
Drug type listedBrand-name and compoundedBrand-name and compounded
Consultation$0 in the record; current conditions unconfirmedIncluded in the record; current conditions unconfirmed
Pharmacy licenseNot independently verified. Obtain the dispensing pharmacy name and verify its state license.Not independently verified. Obtain the dispensing pharmacy name and verify its state license.
Reported states47; confirm eligibility and clinician licensing in your state49; confirm eligibility and clinician licensing in your state
CancellationCancellation reported; notice, minimum term and refund conditions unconfirmedCancellation reported; notice, minimum term and refund conditions unconfirmed
Clinician/support as reportedLicensed clinicians via online consultationLicensed physicians, unlimited visits, 24/7 messaging
Recorded provider check2026-09-022026-09-26

Which should you choose?

Ask each provider for the full cost at your prescribed dose, required labs and visits, the dispensing pharmacy, the clinician's state license, renewal charges and written refund terms. Compare those answers with your clinician.

Compounded drugs are not FDA-approved and do not undergo FDA review for safety, effectiveness or quality before marketing. FDA source and recommendations.

GobyMeds: evidence and terms

Read GobyMeds's sourced record · GobyMeds source

Visit GobyMeds

MEDVi: evidence and terms

Recorded FDA letter (2026-02-20): FDA found claims on medvi.io for compounded GLP-1 products false or misleading, making the products misbranded under FD&C Act sections 502(a) and 502(bb). FDA letter.

Read MEDVi's sourced record · MEDVi source

Visit MEDVi

Compare the full provider directory · Compare recorded price subtotals

Compare providersVisit Embody →